Education
About Us
Working with TipRanks
Follow Us
BioAge Labs, Inc. (BIOA)
NASDAQ:BIOA
BIOA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.88 - $26.62
Previous CloseN/A
Volume146.35K
Average Volume (3M)131.29K
Market Cap
$170.65M
Enterprise Value-$140.49M
Total Cash (Recent Filing)$297.30M
Total Debt (Recent Filing)$8.75M
Price to Earnings (P/E)―
Beta1.44
Next Earnings
Nov 06, 2025EPS Estimate
-0.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.60
Shares Outstanding35,850,037
10 Day Avg. Volume219,932
30 Day Avg. Volume131,290
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-0.82
Enterprise Value/Revenue-36.37
Enterprise Value/Gross Profit-36.92
Enterprise Value/Ebitda1.72
Forecast
1Y Price Target
$5.00Price Target Upside5.04% Upside
Rating ConsensusModerate Sell
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Financial StabilityBioAge Labs has a strong cash position, with $313.4M in cash and equivalents, expected to support operations through 2029.
Pipeline ExpansionThe next-generation APJ agonist pipeline was recently expanded, featuring a novel antibody with significantly greater potency.
Research And DevelopmentDiscovery collaborations with major companies like Novartis and Lilly are progressing, focusing on novel targets related to aging and exercise.
Bears Say
Clinical Data UncertaintyMaintain Underweight rating as clinical data for clarity on the early stage pipeline is awaited.
Financial PerformanceBioAge reported a net loss of $21.6 million for the second quarter, resulting in a loss of $0.60 per share, which was greater than the estimate of a net loss of $15.0 million, or a loss of $0.41 per share.
Pipeline ChallengesOverall, caution remains as the APJ agonist pipeline resets, given prior challenges.
BioAge Labs, Inc. News
BIOA FAQ
What was BioAge Labs, Inc.’s price range in the past 12 months?
BioAge Labs, Inc. lowest stock price was $2.88 and its highest was $26.62 in the past 12 months.
What is BioAge Labs, Inc.’s market cap?
BioAge Labs, Inc.’s market cap is $170.65M.
When is BioAge Labs, Inc.’s upcoming earnings report date?
BioAge Labs, Inc.’s upcoming earnings report date is Nov 06, 2025 which is in 59 days.
How were BioAge Labs, Inc.’s earnings last quarter?
BioAge Labs, Inc. released its earnings results on Aug 06, 2025. The company reported -$0.6 earnings per share for the quarter, missing the consensus estimate of -$0.482 by -$0.118.
Is BioAge Labs, Inc. overvalued?
According to Wall Street analysts BioAge Labs, Inc.’s price is currently Undervalued.
Does BioAge Labs, Inc. pay dividends?
BioAge Labs, Inc. does not currently pay dividends.
What is BioAge Labs, Inc.’s EPS estimate?
BioAge Labs, Inc.’s EPS estimate is -0.58.
How many shares outstanding does BioAge Labs, Inc. have?
BioAge Labs, Inc. has 35,850,037 shares outstanding.
What happened to BioAge Labs, Inc.’s price movement after its last earnings report?
BioAge Labs, Inc. reported an EPS of -$0.6 in its last earnings report, missing expectations of -$0.482. Following the earnings report the stock price went down -0.231%.
Which hedge fund is a major shareholder of BioAge Labs, Inc.?
Currently, no hedge funds are holding shares in BIOA
BioAge Labs, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
$5.00 (5.04% Upside)
$5.00 (5.04% Upside)
Hedge Fund Trend
Decreased
By 1.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.3%
Last 30 Days ▲ 1.2%
Last 30 Days ▲ 1.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Fundamentals
Return on Equity
-35.88%
Trailing 12-Months
Asset Growth
95.95%
Trailing 12-Months
Company Description
BioAge Labs, Inc.
BioAge Labs, Inc. (BIOA) is a biotechnology company focused on developing innovative therapies aimed at extending healthy human lifespan by targeting the molecular pathways associated with aging. The company leverages its proprietary platform to identify and validate drug targets that can modulate key biological processes involved in aging. BioAge's core products include a pipeline of therapeutic candidates designed to treat age-related diseases and improve healthspan.
BIOA Stock 12 Month Forecast
Average Price Target
$5.00
▲(5.04% Upside)
Technical Analysis
Ownership Overview
13.57% Insiders
2.83% Mutual Funds
43.25% Other Institutional Investors
33.59% Public Companies and
Individual Investors